Opus Genetics (NASDAQ:IRD – Get Free Report) had its price objective cut by analysts at Jones Trading from $9.00 to $8.00 in a research report issued on Tuesday,Benzinga reports. The firm currently h… [+1737 chars]...
Read moreHC Wainwright restated their buy rating on shares of Opus Genetics (NASDAQ:IRD – Free Report) in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a $8.00 t… [+1509 chars]...
Read moreOpus Genetics, Inc. (NASDAQ:IRD – Free Report) – Analysts at HC Wainwright reduced their FY2025 EPS estimates for shares of Opus Genetics in a research report issued to clients and investors on Tuesd… [+2115 chars]...
Read moreOpus Genetics, Inc. (NASDAQ:IRD – Free Report) – Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for shares of Opus Genetics in a note issued to investors on Tuesday, April 1… [+2082 chars]...
Read moreMersana Therapeutics (NASDAQ:MRSN – Get Free Report) and Opus Genetics (NASDAQ:IRD – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the t… [+4389 chars]...
Read moreBoard Timed Highly Dilutive Financing to Close on the Record Date for the Annual Meeting, Tilting the Vote and Forcing the Withdrawal of the Restore Value Slate Second Major Transaction in Six Month… [+21245 chars]...
Read more